Halozyme Therapeutics Inc (NASDAQ:HALO)

18.86
Delayed Data
As of 4:00pm ET
 -0.30 / -1.57%
Today’s Change
11.41
Today|||52-Week Range
21.48
-6.91%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 1
2017
Quarter 2
2017
Quarter 3
2017
Quarter 4
2017
Revenue and IncomeNet Revenues29.6M33.8M63.7M189.6M
 
 
 
 
 
Cost of Goods Sold6.9M7.2M7.8M7.0M
 
 
 
 
 
Depreciation And Amortization602.0K600.0K500.0K493.0K
 
 
 
 
 
 
Operating ExpensesGross Income22.0M26.0M55.4M182.1M
 
 
 
 
 
General Expenses49.6M51.4M47.3M56.1M
 
 
 
 
 
Research And Development36.9M38.3M34.0M41.4M
 
 
 
 
 
Total Operating Expenses57.1M59.2M55.7M63.6M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-27.5M-25.5M8.1M125.9M
 
 
 
 
 
Interest Expense On Debt5.4M5.5M5.5M5.5M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-32.7M-30.6M3.3M121.6M
 
 
 
 
 
Income Taxes-210.0K-180.0K-580.0K-2.3M
 
 
 
 
 
Net Income-32.9M-30.8M2.7M123.9M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS128.6M134.0M141.2M141.7M
 
 
 
 
 
Shares To Calculate EPS Diluted128.6M134.0M143.2M145.6M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.26-$0.23$0.02$0.85
 
 
 
 
 
EPS Diluted-$0.26-$0.23$0.02$0.85